Operationally ready by 2029, it will be the Company’s
first-ever facility to cover the full manufacturing process for ADCs
澳门在线赌城娱乐 intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC portfolio. ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody.
The planned greenfield facility, supported by the Singapore Economic Development Board (EDB), will be 澳门在线赌城娱乐’s first end-to-end ADC production site, fully incorporating all steps of the manufacturing process at a commercial scale. Manufacturing of ADCs is a multi-step process that comprises antibody production, synthesis of chemotherapy drug and linker, conjugation of drug-linker to the antibody, and filling of the completed ADC substance.
彭昌文, 主席, EDB said: "We welcome 澳门在线赌城娱乐's decision to establish a manufacturing presence in Singapore for the first time. It will also be a first for 澳门在线赌城娱乐 – an end-to-end manufacturing facility for novel antibody drug conjugates that enables precision therapy for cancer. This greenfield investment is a strong show of confidence in Singapore's biopharmaceutical manufacturing capabilities and talent, strengthens our ecosystem in supporting the 发展 and manufacturing of precision medicines, and creates meaningful jobs and economic opportunities for Singapore. We look forward to a successful partnership with 澳门在线赌城娱乐."
帕斯卡Soriot, 首席执行官, 澳门在线赌城娱乐, said: “澳门在线赌城娱乐 has built an industry-leading portfolio of cancer medicines including antibody drug conjugates which have shown enormous potential to replace traditional chemotherapy for patients across many settings. Singapore is one of the world’s most attractive countries for investment given its reputation for excellence in complex manufacturing, and I am excited for 澳门在线赌城娱乐 to locate our $1.5 billion ADC manufacturing facility in the country.”
澳门在线赌城娱乐 has a broad portfolio of in-house ADCs including six wholly owned ADCs in the clinic and many more in preclinical 发展.
As part of 澳门在线赌城娱乐's commitment to driving sustainability in healthcare, the Company will work with Singapore's government and other partners on green solutions for the ADC facility. This facility will be designed to emit zero carbon from its first day of operations.
澳门在线赌城娱乐 aims to begin design and construction of the manufacturing facility by the end of 2024, with targeted operational readiness from 2029.
笔记
澳门在线赌城娱乐
澳门在线赌城娱乐 (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, 发展, and commercialisation of prescription medicines in 肿瘤学, 罕见疾病, 和澳门第一赌城在线娱乐, 包括心血管, 肾 & 新陈代谢和呼吸 & 免疫学. 总部设在剑桥, UK, 澳门在线赌城娱乐 operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 请访问 澳门在线赌城娱乐.com and follow the Company on 社交媒体 @澳门在线赌城娱乐.
联系人
For details on how to contact the 投资者关系 Team, please click 在这里. 对于“媒体联系人”，单击 在这里.